Advisory Committee on Immunization Practices (ACIP); Amended Notice of Meeting, 67752-67753 [2023-21566]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
67752
Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices
young women, or in related disciplines
with a specific focus on young women.
DATES: Nominations for membership on
the ACBCYW must be received no later
than November 10, 2023. Packages
received after this time will not be
considered for the current membership
cycle.
ADDRESSES: All nominations should be
mailed to Kimberly E. Smith, MBA,
MHA. c/o ACBCYW Secretariat, Centers
for Disease Control and Prevention,
3719 North Peachtree Road, Building
100, Chamblee, Georgia 30341 or
emailed (recommended) to acbcyw@
cdc.gov.
FOR FURTHER INFORMATION CONTACT:
Kimberly E. Smith, MBA, MHA,
Designated Federal Officer, National
Center for Chronic Disease Prevention
and Health Promotion, CDC, 4770
Buford Highway NE, Mailstop S107–4,
Atlanta, Georgia 30341, Telephone:
(404) 498–0073; acbcyw@cdc.gov.
SUPPLEMENTARY INFORMATION:
Nominations are being sought for
individuals who have expertise and
qualifications necessary to contribute to
the accomplishments of the committee’s
objectives. Nominees will be selected
based on expertise in the fields of breast
health, breast cancer, disease prevention
and risk reduction, survivorship
(including metastatic breast cancer),
hereditary breast and ovarian cancer
(HBOC), or in related disciplines with a
specific focus on young women. Persons
with personal experience with early
onset breast cancer are also eligible to
apply. This includes but may not be
limited to breast cancer survivors <45
years of age and caregivers of said
persons. Federal employees will not be
considered for membership. Members
may be invited to serve up to four-year
terms. Selection of members is based on
candidates’ qualifications to contribute
to the accomplishment of ACBCYW
objectives (https://www.cdc.gov/maso/
facm/facmacbcyw.html).
The U.S. Department of Health and
Human Services policy stipulates that
committee membership be balanced in
terms of points of view represented, and
the committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
and cannot be full-time employees of
the U.S. Government. Current
participation on federal workgroups or
prior experience serving on a federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
VerDate Sep<11>2014
18:41 Sep 29, 2023
Jkt 262001
advisory committees and multiple
committee memberships. Committee
members are Special Government
Employees, requiring the filing of
financial disclosure reports at the
beginning and annually during their
terms. CDC reviews potential candidates
for ACBCYW membership each year and
provides a slate of nominees for
consideration to the Secretary of HHS
for final selection. HHS notifies selected
candidates of their appointment near
the start of the term in November 2024,
or as soon as the HHS selection process
is completed. Note that the need for
different expertise varies from year to
year and a candidate who is not selected
in one year may be reconsidered in a
subsequent year. SGE nominees must be
U.S. citizens and cannot be full-time
employees of the U.S. Government.
Candidates should submit the following
items:
D Current curriculum vitae, including
complete contact information
(telephone numbers, mailing address,
email address).
D At least one letter of
recommendation from person(s) not
employed by the U.S. Department of
Health and Human Services.
(Candidates may submit letter(s) from
current HHS employees if they wish,
but at least one letter must be submitted
by a person not employed by an HHS
agency (e.g., CDC, NIH, FDA, etc.).
D A short biography (150 words or
less).
Nominations may be submitted by the
candidate him- or herself, or by the
person/organization recommending the
candidate.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023–21568 Filed 9–29–23; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2023–0076]
Advisory Committee on Immunization
Practices (ACIP); Amended Notice of
Meeting
Centers for Disease Control and
Prevention, Department of Health and
Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
Advisory Committee on Immunization
Practices (ACIP). This meeting is open
to the public.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, Committee
Management Specialist, Advisory
Committee on Immunization Practices,
National Center for Immunization and
Respiratory Diseases, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H24–8,
Atlanta, Georgia 30329–4027.
Telephone: (404) 639–8836; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION: Notice is
hereby given of a change in the meeting
of the Advisory Committee on
Immunization Practices (ACIP);
September 22, 2023, 10 a.m. to 5 p.m.,
EDT (times subject to change, see the
ACIP website for updates: https://
www.cdc.gov/vaccines/acip/index.
html), in the original Federal Register
notice.
Notice of the virtual meeting was
published in the Federal Register on
September 6, 2023, Volume 88, Number
171, pages 60945–60946.
Notice of the virtual meeting is being
amended to add an additional agenda
item in the matters to be considered,
which should read as follows:
Matters to be Considered: The agenda
will include discussions of maternal
respiratory syncytial virus (RSV)
vaccine, child/adolescent immunization
schedules and adult immunization
schedule. A recommendation vote for
maternal RSV vaccine is scheduled. A
Vaccines for Children vote is scheduled
for maternal RSV vaccine. Agenda items
are subject to change as priorities
dictate. For more information on the
meeting agenda, visit https://
www.cdc.gov/vaccines/acip/meetings/
index.html.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
SUMMARY:
E:\FR\FM\02OCN1.SGM
02OCN1
Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023–21566 Filed 9–29–23; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2023–0082]
Advisory Committee to the Director,
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with regulatory
provisions, the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
Advisory Committee to the Director,
Centers for Disease Control and
Prevention (ACD, CDC). This is a hybrid
meeting, accessible both in person and
virtually (webcast live via the World
Wide Web). It is open to the public and
limited only by the space available.
Time will be available for public
comment.
SUMMARY:
The meeting will be held on
November 14, 2023, from 9:00 a.m. to
4:00 p.m., EST (times subject to change).
Written comments must be received
on or before October 27, 2023.
ADDRESSES:
Meeting address: CDC Roybal
Campus, Building 19, Auditorium B3,
1600 Clifton Road NE, Atlanta, Georgia
30329–4027.
Please note that the meeting location,
the CDC Roybal Campus, is a federal
facility and in-person access is limited
to United States citizens unless prior
authorizations, taking up to 30 to 60
days, have been made. Visitors must
follow all directions for access to CDC
facilities. Directions for visitors to CDC,
including safety requirements related to
COVID–19; are available at https://
www.cdc.gov/screening/visitors.html.
lotter on DSK11XQN23PROD with NOTICES1
DATES:
VerDate Sep<11>2014
18:41 Sep 29, 2023
Jkt 262001
Registration: You must register to
attend this meeting in person. If you
wish to attend in person, please submit
a request by email to ACDirector@
cdc.gov or by telephone at (404) 345–
1039 at least 5 business days in advance
of the meeting. No registration is
required to view the meeting via the
World Wide Web. Information for
accessing the webcast will be available
at https://www.cdc.gov/about/advisorycommittee-director/.
Written comments: You may submit
comments, identified by Docket No.
CDC–2023–0082, by either of the
methods listed below. Do not submit
comments for the docket by email. CDC
does not accept comments for the
docket by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Bridget Richards, MPH,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
Mailstop H21–10, Atlanta, Georgia
30329–4027. Attn: Docket No. CDC–
2023–0082.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://www.regulations.gov,
including any personal information
provided. For access to the docket to
read background documents or
comments received, go to https://
www.regulations.gov. Written comments
received in advance of the meeting will
be included in the official record of the
meeting.
FOR FURTHER INFORMATION CONTACT:
Bridget Richards, MPH, Office of the
Chief of Staff, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop H21–10, Atlanta,
Georgia 30329–4027; Telephone: (404)
345–1039; Email: ACDirector@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee to
the Director, CDC, shall (1) make
recommendations to the Director
regarding ways to prioritize the
activities of the agency in alignment
with the CDC Strategic Plan required
under section 305(c); H.R. 2617–1252;
(2) advise on ways to achieve or
improve performance metrics in relation
to the CDC Strategic Plan, and other
relevant metrics, as appropriate; (3)
provide advice and recommendations
on the development of the Strategic
Plan, and any subsequent updates, as
appropriate; (4) advise on grant,
cooperative agreements, contracts, or
other transactions, as applicable; (5)
provide other advice to the Director, as
requested, to fulfill duties under
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
67753
sections 301 and 311; and (6) appoint
subcommittees. The Committee
recommends ways to prioritize CDC’s
activities, improve results, and address
health disparities. It also provides
guidance to help CDC work more
effectively with its various private and
public sector constituents to make
health protection a practical reality.
Matters to be Considered: The agenda
will include an introduction of the new
CDC Director, Dr. Mandy Cohen, and a
discussion regarding agency updates
and priorities. The agenda also includes
updates on the progress made to date on
the health equity, laboratory, and data
and surveillance recommendation;
discussion and vote on the Laboratory
Workgroup final recommendations; and
discussion and votes to sunset the
Health Equity and Laboratory
workgroups due to completion of their
terms of reference. CDC’s Senior
Advisor for Health Strategy will present
on supporting healthy families, and a
Senior Counselor to the CDC Director
will present on COVID–19 recission.
Agenda items are subject to change as
priorities dictate.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on October 2, 2023 through
October 27, 2023.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
E:\FR\FM\02OCN1.SGM
02OCN1
]]>Agencies
[Federal Register Volume 88, Number 189 (Monday, October 2, 2023)]
[Notices]
[Pages 67752-67753]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21566]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2023-0076]
Advisory Committee on Immunization Practices (ACIP); Amended
Notice of Meeting
AGENCY: Centers for Disease Control and Prevention, Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC),
announces the following meeting of the Advisory Committee on
Immunization Practices (ACIP). This meeting is open to the public.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management
Specialist, Advisory Committee on Immunization Practices, National
Center for Immunization and Respiratory Diseases, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta,
Georgia 30329-4027. Telephone: (404) 639-8836; Email: [email protected].
SUPPLEMENTARY INFORMATION: Notice is hereby given of a change in the
meeting of the Advisory Committee on Immunization Practices (ACIP);
September 22, 2023, 10 a.m. to 5 p.m., EDT (times subject to change,
see the ACIP website for updates: https://www.cdc.gov/vaccines/acip/), in the original Federal Register notice.
Notice of the virtual meeting was published in the Federal Register
on September 6, 2023, Volume 88, Number 171, pages 60945-60946.
Notice of the virtual meeting is being amended to add an additional
agenda item in the matters to be considered, which should read as
follows:
Matters to be Considered: The agenda will include discussions of
maternal respiratory syncytial virus (RSV) vaccine, child/adolescent
immunization schedules and adult immunization schedule. A
recommendation vote for maternal RSV vaccine is scheduled. A Vaccines
for Children vote is scheduled for maternal RSV vaccine. Agenda items
are subject to change as priorities dictate. For more information on
the meeting agenda, visit https://www.cdc.gov/vaccines/acip/meetings/.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease
[[Page 67753]]
Control and Prevention, has been delegated the authority to sign
Federal Register notices pertaining to announcements of meetings and
other committee management activities, for both the Centers for Disease
Control and Prevention and the Agency for Toxic Substances and Disease
Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-21566 Filed 9-29-23; 8:45 am]
BILLING CODE 4163-18-P
